Literature DB >> 21056429

A serological analysis of viral and bacterial infections associated with neuromyelitis optica.

Michiaki Koga1, Toshiyuki Takahashi, Motoharu Kawai, Kazuo Fujihara, Takashi Kanda.   

Abstract

To evaluate the role of infections in the development of neuromyelitis optica (NMO), 19 patients positive for anti-aquaporin-4 antibody were screened for 24 viral and bacterial infections. Serological evidence of recent viral infection was found in 7 of 15 patients screened during the acute phase of the neurologic illness, which was a significantly more frequent rate of infection than seen in the control group of 33 patients with neurodegenerative, metabolic, or vertebral diseases (47% versus 15%). Mumps virus and human herpes viruses were the frequent causal agents, although there was no statistical difference in frequency between the two groups. Most patients with identified recent infection had monophasic or recurrent myelitis without evidence of optic nerve involvement and small number of total clinical relapses. Disease history tended to be shorter in patients with identified recent infection than those without, and an expanded long spinal cord lesion in magnetic resonance imaging was rarely found in patients with identified recent infection, although statistical significance could not be shown. These findings indicate that, not single, but various viral infections, can be associated with the development of NMO during the early stages of the illness, although the exact pathogenesis of NMO has yet to be clarified.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056429     DOI: 10.1016/j.jns.2010.10.013

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

1.  Effects of age and sex on aquaporin-4 autoimmunity.

Authors:  Amy M L Quek; Andrew McKeon; Vanda A Lennon; Jayawant N Mandrekar; Raffaele Iorio; Yujuan Jiao; Chiara Costanzi; Brian G Weinshenker; Dean M Wingerchuk; Claudia F Lucchinetti; Elizabeth A Shuster; Sean J Pittock
Journal:  Arch Neurol       Date:  2012-08

Review 2.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

3.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

Review 4.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 5.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

6.  Epstein - Barr virus Infection in a Patient with Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: A Case Report and Review of Literature.

Authors:  Justin B Levinson; Milena Rodriguez Alvarez; Kristaq Koci; Aleksander Feoktistov; Isabel M McFarlane
Journal:  Clin Case Rep Rev       Date:  2018-05-31

Review 7.  Immunotherapy of neuromyelitis optica.

Authors:  Benjamin Bienia; Roumen Balabanov
Journal:  Autoimmune Dis       Date:  2013-12-25

8.  A case of neuromyelitis optica masquerading as miller fisher syndrome.

Authors:  Yuka Furutani; Masayuki Hata; Kazuaki Miyamoto; Yusaku Moribata; Nagahisa Yoshimura
Journal:  Case Rep Neurol       Date:  2014-10-04

Review 9.  Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors.

Authors:  Tatiana Koudriavtseva; Rosaria Renna; Domenico Plantone; Caterina Mainero
Journal:  Front Neurol       Date:  2015-03-24       Impact factor: 4.003

Review 10.  The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Authors:  Michalina Jasiak-Zatonska; Alicja Kalinowska-Lyszczarz; Slawomir Michalak; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2016-03-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.